Relugolix is the first and only, orally-administered GnRH receptor antagonist approved for the treatment of several hormone-responsive conditions, including prostate cancer - similar therapies require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients
Product Name |
Relugolix |
CAS Number |
737789-87-6 |
Therapeutic Class |
Anti-endometriosis, Antineoplastic |
Dosage Form |
Oral Tablet |
Availability |
Under Evaluation |
Regulatory Status |
|